Searched for: in-biosketch:yes
person:morgag04
Non-homologous end-joining gene profiling reveals distinct expression patterns associated with lymphoma and multiple myeloma
Roddam, Philippa L; Allan, James M; Dring, Ann M; Worrillow, Lisa J; Davies, Faith E; Morgan, Gareth J
Repair of DNA strand breaks induced during lymphoid antigen receptor rearrangement involves non-homologous end-joining (NHEJ). We investigated NHEJ in the aetiology of lymphoproliferative disorders (LPDs) and the disease subtypes therein through real-time quantitative RT-PCR gene expression analysis. Lower expression of XRCC6 and MRE11A was observed in all tumours, with higher expression of both XRCC4 and RAD50 observed only in multiple myeloma (MM). Hierarchical clustering enabled tumours to be clearly distinguished from controls, and by morphological sub-type. We postulate this identifies targets worthy of investigation in the genetic predisposition, pathogenesis and prognosis of lymphoid malignancies.
PMID: 20148879
ISSN: 1365-2141
CID: 3647592
Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome
Dickens, Nicholas J; Walker, Brian A; Leone, Paola E; Johnson, David C; Brito, José L; Zeisig, Athanasia; Jenner, Matthew W; Boyd, Kevin D; Gonzalez, David; Gregory, Walter M; Ross, Fiona M; Davies, Faith E; Morgan, Gareth J
PURPOSE/OBJECTIVE:Myeloma is a clonal malignancy of plasma cells. Poor-prognosis risk is currently identified by clinical and cytogenetic features. However, these indicators do not capture all prognostic information. Gene expression analysis can be used to identify poor-prognosis patients and this can be improved by combination with information about DNA-level changes. EXPERIMENTAL DESIGN/METHODS:Using single nucleotide polymorphism-based gene mapping in combination with global gene expression analysis, we have identified homozygous deletions in genes and networks that are relevant to myeloma pathogenesis and outcome. RESULTS:We identified 170 genes with homozygous deletions and corresponding loss of expression. Deletion within the "cell death" network was overrepresented and cases with these deletions had impaired overall survival. From further analysis of these events, we have generated an expression-based signature associated with shorter survival in 258 patients and confirmed this signature in data from two independent groups totaling 800 patients. We defined a gene expression signature of 97 cell death genes that reflects prognosis and confirmed this in two independent data sets. CONCLUSIONS:We developed a simple 6-gene expression signature from the 97-gene signature that can be used to identify poor-prognosis myeloma in the clinical environment. This signature could form the basis of future trials aimed at improving the outcome of poor-prognosis myeloma.
PMCID:2841345
PMID: 20215539
ISSN: 1078-0432
CID: 3647602
Transfection of siRNAs in multiple myeloma cell lines
Brito, Jose L R; Brown, Nicola; Morgan, Gareth J
RNA interference (RNAi), a valuable tool to specifically silence gene expression, is becoming an indispensable weapon in the arsenal of functional genomics, target validation and gene-specific therapeutic research. We have shown that Streptolysin-O (SLO) reversible permeabilization is an efficient method to deliver small interfering RNAs (siRNAs) to hard-to-transfect human myeloma cell lines. In addition, we have shown that transfection of siRNAs, using the SLO reversible permeabilization, specifically and efficiently induces gene silencing in myeloma cell lines.
PMID: 20217559
ISSN: 1940-6029
CID: 3647612
A polymorphism in the 3' UTR of IRF4 linked to susceptibility and pathogenesis in chronic lymphocytic leukaemia and Hodgkin lymphoma has limited impact in multiple myeloma [Letter]
Pratt, Guy; Fenton, James A L; Allsup, David; Fegan, Chris; Morgan, Gareth J; Jackson, Graham; Sunter, Nicola J; Hall, Andrew G; Irving, Julie A E; Allan, James M
PMID: 20408839
ISSN: 1365-2141
CID: 3647622
The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance
Ross, Fiona M; Chiecchio, Laura; Dagrada, GianPaolo; Protheroe, Rebecca K M; Stockley, David M; Harrison, Christine J; Cross, Nicholas C P; Szubert, Alex J; Drayson, Mark T; Morgan, Gareth J
A large series of plasma cell dyscrasias (n=2207) was examined for translocations which deregulate the MAF genes, t(14;20)(q32;q12) and t(14;16)(q32;q23), and their disease behavior was compared to a group characterized by the t(4;14)(p16;q32) where CCND2 is also up-regulated. The t(14;20) showed low prevalence in myeloma (27/1830, 1.5%) and smoldering myeloma (1/148, <1%) with a higher incidence in MGUS (9/193, 5% P=0.005). Strong associations with del(13) (76%), non-hyperdiploidy (83%) and gain of 1q (58%) were seen but no association with an IgA M-protein or absence of bone disease was noted. All three translocations were associated with poor outcome in myeloma, but strikingly all t(14;20) MGUS/smoldering myeloma cases (n=10) had stable, low level disease. In contrast, the 10 t(14;16) and 25 t(4;14) MGUS/smoldering myeloma cases were associated with both evolving and non-evolving disease. None of the associated genetic abnormalities helped to predict for progression from MGUS or smoldering myeloma.
PMCID:2895050
PMID: 20410185
ISSN: 1592-8721
CID: 3647632
XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments
Bagratuni, Tina; Wu, Ping; Gonzalez de Castro, David; Davenport, Emma L; Dickens, Nicholas J; Walker, Brian A; Boyd, Kevin; Johnson, David C; Gregory, Walter; Morgan, Gareth J; Davies, Faith E
Immunoglobulin production by myeloma plasma cells depends on the unfolded protein response for protein production and folding. Recent studies have highlighted the importance of IRE1alpha and X box binding protein 1 (XBP1), key members of this pathway, in normal B-plasma cell development. We have determined the gene expression levels of IRE1alpha, XBP1, XBP1UNSPLICED (XBP1u), and XBP1SPLICED (XBP1s) in a series of patients with myeloma and correlated findings with clinical outcome. We show that IRE1alpha and XBP1 are highly expressed and that patients with low XBP1s/u ratios have a significantly better overall survival. XBP1s is an independent prognostic marker and can be used with beta2 microglobulin and t(4;14) to identify a group of patients with a poor outcome. Furthermore, we show the beneficial therapeutic effects of thalidomide in patients with low XBP1s/u ratios. This study highlights the importance of XBP1 in myeloma and its significance as an independent prognostic marker and as a predictor of thalidomide response.
PMID: 20421453
ISSN: 1528-0020
CID: 3647642
The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study
Schey, Stephen A; Morgan, Gareth J; Ramasamy, Karthik; Hazel, Beth; Ladon, Dariusz; Corderoy, Sophie; Jenner, Matthew; Phekoo, Karen; Boyd, Kevin; Davies, Faith E
We report the results of a Phase I/II dose escalation study to determine the maximum tolerated dose (MTD) of cyclophosphamide when combined with lenalidomide and dexamethasone in relapsed/refractory myeloma. Thirty-one patients were enrolled in cohorts of 3, at five dose levels of cyclophosphamide to a maximum of 700 mg on days 1 and 8 of a 28-d cycle. Patients received lenalidomide 25 mg days 1-21 and dexamethasone 20 mg orally days 1-4 and 8-11. The MTD was 600 mg cyclophosphamide, days 1 and 8. Grade 3/4 haematological complications occurred in 26% of patients, grade 3/4 infection in 3% (both at 700 mg cyclophosphamide), with thromboembolic complications in 6% of patients. Overall complete response (CR) rate was 29%, very good partial response rate 7% and partial response rate 45% giving an overall response rate of 81%. After 21 months median follow-up, projected 2-year progression-free survival was 56%, with 80% overall survival at 30 months. Ten further patients were treated at MTD with a 40% CR rate. No dose reductions for any study drugs or deaths occurred during cycles 1-9. Lenalidomide, cyclophosphamide and dexamethasone is a safe, effective combination in relapsed myeloma inducing a high response rate, warranting further investigation in phase III trials.
PMID: 20553268
ISSN: 1365-2141
CID: 3647652
Radiolucent retractor for angiographic analysis during hybrid congenital cardiac procedures
Morgan, Gareth J; Clarke, Karen; Caldarone, Christopher; Benson, Lee N
PMID: 20599228
ISSN: 1097-685x
CID: 3647662
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value
Walker, Brian A; Leone, Paola E; Chiecchio, Laura; Dickens, Nicholas J; Jenner, Matthew W; Boyd, Kevin D; Johnson, David C; Gonzalez, David; Dagrada, Gian Paolo; Protheroe, Rebecca K M; Konn, Zoe J; Stockley, David M; Gregory, Walter M; Davies, Faith E; Ross, Fiona M; Morgan, Gareth J
To obtain a comprehensive genomic profile of presenting multiple myeloma cases we performed high-resolution single nucleotide polymorphism mapping array analysis in 114 samples alongside 258 samples analyzed by U133 Plus 2.0 expression array (Affymetrix). We examined DNA copy number alterations and loss of heterozygosity (LOH) to define the spectrum of minimally deleted regions in which relevant genes of interest can be found. The most frequent deletions are located at 1p (30%), 6q (33%), 8p (25%), 12p (15%), 13q (59%), 14q (39%), 16q (35%), 17p (7%), 20 (12%), and 22 (18%). In addition, copy number-neutral LOH, or uniparental disomy, was also prevalent on 1q (8%), 16q (9%), and X (20%), and was associated with regions of gain and loss. Based on fluorescence in situ hybridization and expression quartile analysis, genes of prognostic importance were found to be located at 1p (FAF1, CDKN2C), 1q (ANP32E), and 17p (TP53). In addition, we identified common homozygously deleted genes that have functions relevant to myeloma biology. Taken together, these analyses indicate that the crucial pathways in myeloma pathogenesis include the nuclear factor-κB pathway, apoptosis, cell-cycle regulation, Wnt signaling, and histone modifications. This study was registered at http://isrctn.org as ISRCTN68454111.
PMID: 20616218
ISSN: 1528-0020
CID: 3647672
High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma [Letter]
Boyd, Kevin D; Walker, Brian A; Wardell, Christopher P; Ross, Fiona M; Gregory, Walter M; Davies, Faith E; Morgan, Gareth J
PMID: 20858096
ISSN: 1029-2403
CID: 3647682